Immunic (NASDAQ:IMUX - Get Free Report) had its price objective decreased by analysts at HC Wainwright from $8.00 to $5.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 390.20% from the company's current price.
A number of other research firms have also weighed in on IMUX. D. Boral Capital decreased their target price on shares of Immunic from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Friday, February 13th. Chardan Capital upgraded Immunic to a "strong-buy" rating in a research report on Wednesday, November 19th. Roth Mkm began coverage on Immunic in a research note on Friday, November 7th. They set a "buy" rating and a $3.00 price objective for the company. Brookline Capital Acquisition upgraded Immunic to a "strong-buy" rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Immunic in a report on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $6.00.
Read Our Latest Stock Analysis on IMUX
Immunic Stock Performance
NASDAQ:IMUX opened at $1.02 on Monday. The business's fifty day moving average is $0.70 and its 200 day moving average is $0.76. The firm has a market cap of $133.07 million, a price-to-earnings ratio of -1.46 and a beta of 1.45. Immunic has a 52-week low of $0.51 and a 52-week high of $1.35.
Immunic (NASDAQ:IMUX - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). Equities analysts predict that Immunic will post -0.94 EPS for the current fiscal year.
Institutional Investors Weigh In On Immunic
Large investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd bought a new stake in Immunic during the third quarter worth about $29,000. Two Sigma Investments LP purchased a new position in shares of Immunic during the 3rd quarter valued at about $52,000. HB Wealth Management LLC bought a new stake in Immunic in the 3rd quarter worth approximately $81,000. Seven Fleet Capital Management LP bought a new stake in Immunic in the 4th quarter worth approximately $83,000. Finally, Virtu Financial LLC purchased a new stake in Immunic in the third quarter worth approximately $99,000. Hedge funds and other institutional investors own 51.82% of the company's stock.
Immunic Company Profile
(
Get Free Report)
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
